Company Encyclopedia
View More
name
Madrigal Pharma
MDGL.US
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
1.946 T
MDGL.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking60/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-41.22%E
    • Profit Margin-39.04%E
    • Gross Margin93.69%A
  • Growth ScoreA
    • Revenue YoY864.21%A
    • Net Profit YoY44.26%B
    • Total Assets YoY26.95%A
    • Net Assets YoY-19.48%E
  • Cash ScoreB
    • Cash Flow Margin-256.17%D
    • OCF YoY864.21%A
  • Operating ScoreB
    • Turnover0.61B
  • Debt ScoreC
    • Gearing Ratio54.07%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Madrigal Pharmaceuticals Insider Sold Shares Worth $1,380,816, According to a Recent SEC Filing

    Madrigal Pharmaceuticals Insider Sold Shares Worth $1,380,816, According to a Recent SEC Filing

    marketscreener·
    US
    MDGL
    +1.09%
    marketscreener·
    US
    MDGL
    +1.09%

    CEO Sibold Files To Sell 2,400 Of Madrigal Pharmaceuticals Inc [MDGL]

    CEO Sibold William John of Madrigal Pharmaceuticals Inc filed a Form 144 with the SEC to sell 2,400 restricted shares on December 4, 2025. The sale will be managed by Morgan Stanley Smith Barney LLC. Form 144 is required for selling restricted stock, allowing the owner to sell within 90 days of filing. The Washington Service offers insider trading analysis and data services.

    Reuters·
    US
    MDGL
    +1.09%
    Reuters·
    US
    MDGL
    +1.09%

    Galmed Announces Grant Of New Use Patents For The Combination Of Aramchol And Madrigal Pharmaceuticals

    Galmed Pharmaceuticals Ltd :GALMED ANNOUNCES GRANT OF NEW USE PATENTS FOR THE COMBINATION OF ARAMCHOL AND MADRIGAL PHARMACEUTICALS' REZDIFFRA (RESMETIROM) FOR MASH

    Reuters·
    US
    GLMD
    +5.61%
    Reuters·
    US
    GLMD
    +5.61%

    Galmed Pharmaceuticals Granted New Patent for Combination of Aramchol and Rezdiffra (Resmetirom) for MASH Treatment

    Galmed Pharmaceuticals Ltd. announced the grant of new use patents for combining its drug Aramchol with Madrigal Pharmaceuticals’ Rezdiffra for MASH treatment. The patent, granted in South Korea, extends Aramchol’s U.S. patent protection until July 2042, strengthening its position in combination therapies for MASH.

    Reuters·
    US
    GLMD
    +5.61%
    US
    MDGL
    +1.09%
    Reuters·
    US
    GLMD
    +5.61%
    US
    MDGL
    +1.09%

    Madrigal Pharmaceuticals CFO Mardi Dier Reports Disposal of Common Shares

    Mardi Dier, CFO of Madrigal Pharmaceuticals Inc., reported the disposal of common shares of the company. The full filing is available via EDGAR, the SEC's system. This news brief was created by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    MDGL
    +1.09%
    Reuters·
    US
    MDGL
    +1.09%
    © 2025 Longbridge｜Disclaimer